Citadel Advisors’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $66.7M | Buy |
|
|||||
|
2025
Q2 | $45.3M | Buy |
|
|||||
|
2025
Q1 | $35.3M | Buy |
|
|||||
|
2024
Q4 | $38.1M | Buy |
|
|||||
|
2024
Q3 | $37.1M | Buy |
|
|||||
|
2024
Q2 | $27.7M | Sell |
|
|||||
|
2024
Q1 | $48.4M | Buy |
|
|||||
|
2023
Q4 | $15.8M | Buy |
|
|||||
|
2023
Q3 | $4.05M | Buy |
|
|||||
|
2023
Q2 | $6.45M | Sell |
|
|||||
|
2023
Q1 | $8.04M | Sell |
|
|||||
|
2022
Q4 | $5.47M | Buy |
|
|||||
|
2022
Q3 | $5.78M | Sell |
|
|||||
|
2022
Q2 | $6.93M | Buy |
|
|||||
|
2022
Q1 | $8.38M | Buy |
|
|||||
|
2021
Q4 | $10.7M | Buy |
|
|||||
|
2021
Q3 | $436K | Sell |
|
|||||
|
2021
Q2 | $2.16M | Buy |
|
|||||
|
2021
Q1 | $1.77M | Sell |
|
|||||
|
2020
Q4 | $32.9M | Sell |
|
|||||
|
2020
Q3 | $12.3M | Buy |
|
|||||
|
2020
Q2 | $1.83M | Buy |
|
|||||
|
2020
Q1 | $294K | Buy |
|
|||||
|
2019
Q4 | $126K | Buy |
|
|||||
|
2019
Q3 | $55K | Sell |
|
|||||
|
2019
Q2 | $89K | Sell |
|
|||||
|
2019
Q1 | $104K | Sell |
|
|||||
|
2018
Q4 | $258K | Buy |
|
|||||
|
2018
Q3 | $170K | Buy |
|
|||||
|
2018
Q2 | $138K | Buy |
|
|||||
|
2018
Q1 | – | Sell |
|
|||||
|
2017
Q4 | $52K | Buy |
|
|||||
|
2017
Q3 | – | Hold |
|
|||||
|
2017
Q2 | – | Hold |
|
|||||
|
2017
Q1 | – | Hold |
|
|||||
|
2016
Q4 | – | Hold |
|
|||||
|
2016
Q3 | – | Sell |
|
|||||
|
2016
Q2 | $286K | Buy |
|
|||||
|
2016
Q1 | – | Sell |
|
|||||
|
2015
Q4 | $89K | Buy |
|
|||||
|
2015
Q3 | – | Sell |
|
|||||
|
2015
Q2 | $372K | Buy |
|